{"product_id":"nanogen-nanochip-400-178184775983","title":"Nanogen NanoChip 400","description":"\u003cdiv style=\"display: none;\"\u003e\n\u003ch1\u003eNanogen NanoChip 400\u003c\/h1\u003e\nInformation taken direct from the manufacturer-\"About Nanogen, Inc. Nanogen develops advanced diagnostics to provide physicians and patients worldwide more information to better predict, diagnose and treat disease. The availability of new biomarkers is driving the evolution of medicine, and Nanogen’s vision is to lead the development and growth of advanced diagnostic testing in support of the movement towards individualized healthcare by commercializing a comprehensive portfolio of differentiated products. Diagnostics such as Nanogen’s and those marketed by its subsidiary SYNyX that bring to light information about individuals’ genetic as well as proteomic makeup are facilitating the shift to proactive versus reactive healthcare. Nanogen delivers a variety of products to clinical labs, research institutions and point-of-care testing facilities. These customers are increasing their demand for accurate and reliable diagnostic tools to create a range of tests. These range from single, real-time tests to complex, molecular tests performed on Nanogen’s microarray systems. As a pioneer of nanotechnology and miniaturized biotechnology, Nanogen expects its broad intellectual property portfolio will have diverse applications and licensing opportunities in the future for medical diagnostics as well as other markets. The Opportunity: Molecular Diagnostics Nanogen’s broad suite of diagnostic products makes it possible for the company to take advantage of opportunities in the rapidly growing molecular diagnostics industry. The molecular diagnostics market today is estimated to be approximately $1 billion and is expected to grow at a healthy pace of 30 - 50 percent per year. This growth is fueled by a better understanding of the molecular basis of disease and the need for more genetic tests to improve the prognosis and treatment of patients. Business Strategy Nanogen’s strategy is to identify and commercialize diagnostic tests that meet significant market needs. The company bolstered its capital structure and initiated a business development program to grow its revenue base. The 2004 acquisition of SYNyX provided Nanogen with a variety of point-of-care tests to immediately add to its product portfolio. Later last year, the merger with Epoch Biosciences augmented the product line with 25 complementary analyte specific reagents (ASRs) and other technologies for genetic analysis. These products further leverage Nanogen’s existing sales and marketing infrastructure. Nanogen will continue to identify large volume as well as unique tests with a focus on moving the diagnostic process and information closer to the point of physician and patient interaction. Nanogen will distribute its products around the world through licensing and distribution agreements as well as direct sales efforts to continue to expand its business into new and growing markets in the U.S., Canada and abroad.Products: Addressing Labs’ Needs Molecular Diagnostics \u0026amp; Genetic Testing Available in 2005, the NanoChip® 400 is Nanogen’s second generation advanced molecular diagnostic testing and development platform for clinical research and clinical reference laboratories. The automated multi-purpose system facilitates detection of known genetic sequences using a 400-site NanoChip® Electronic Microarray. The NanoChip® 400 offers increased throughput for running multiplex molecular assays on a smaller sized instrument. Nanogen’s suite of consumable products includes analyte specific reagents (ASRs) for laboratories to develop very simple tests for single mutations or more complex tests for multiple genetic markers. The merger with Epoch Biosciences bolstered Nanogen’s line of ASRs by adding 25 complementary products, allowing Nanogen to offer a broader suite of solutions to its current and targeted customers. These MGB EclipseTM Detection Reagents are compatible with many standard real-time PCR instruments for amplification and quantitation of samples. Nanogen’s internally developed ASRs utilize the NanoChip® microarray for more complex analysis of multiple markers. For example, in 2005 the company will market a panel optimized for use with the NanoChip® 400 that detects the six most common respiratory viruses. The first generation, open platform NanoChip® Molecular Biology Workstation is a resource for researchers identifying the next set of mutations that could be useful as clinical assays. The system’s ability to test a user defined set of mutations, called panels, on one chip makes it easier and more cost-effective to use than research-grade thousand-gene chip arrays. NEXUSdx™ Point-of-Care Diagnostics NEXUSdx™ point-of-care diagnostic tests are marketed to healthcare professionals and research facilities in Europe and Canada by Nanogen’s subsidiary, SYNyX. The highly specialized products diagnose disease at the initial stages to allow for earlier treatment as well as to monitor treatment effectiveness and disease progression. Building expertise in cardiac related health conditions, SYNyX plans to offer an NT-proBNP diagnostic test for congestive heart failure in 2005. Analysts predict the BNP market will have above-average growth and will reach approximately $300 million by 2005 as use increases internationally. Using its Proteomics Discovery Platform™, SYNyX scientists have identified biomarkers in stroke, insulin resistance, type II diabetes, congestive heart failure, Alzheimer's disease and traumatic brain injury. These discovery efforts provide a deep pipeline of potential new and important products for the point-of-care market. Electricity is what makes the NanoChip® different and is a key technological advantage. At the heart of Nanogen's technology is a tiny silicon chip called the NanoChip® Electronic Microarray. The NanoChip® 400 has 400 test sites upon which genetic tests can be conducted. DNA and RNA are moved and concentrated by controlling the current at each test site, improving accuracy, speed and flexibility. Comes as you see. Condition is used and shows minimal signs of use in a working environment. Removed from service in working condition. Does not come with any cables or software other than power cable.In effort to ship item with minimal chance of damage, we will be shipping via freight. Item will be palletized. When purchasing, please provide business name and shipping address that either has a loading dock or forklift so we can keep shipping costs down for you\u003c\/div\u003e\n\n\n\u003cdiv\u003eInformation taken direct from the manufacturer-\u003c\/div\u003e\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\u003cdiv\u003e\"About Nanogen, Inc.\nNanogen develops advanced diagnostics to provide physicians and patients\nworldwide more information to better predict, diagnose and treat disease.\nThe availability of new biomarkers is driving the evolution of medicine, and\nNanogen’s vision is to lead the development and growth of advanced\ndiagnostic testing in support of the movement towards individualized\nhealthcare by commercializing a comprehensive portfolio of differentiated\nproducts. Diagnostics such as Nanogen’s and those marketed by its\nsubsidiary SYNyX that bring to light information about individuals’ genetic as\nwell as proteomic makeup are facilitating the shift to proactive versus\nreactive healthcare.\nNanogen delivers a variety of products to clinical labs, research institutions\nand point-of-care testing facilities. These customers are increasing their\ndemand for accurate and reliable diagnostic tools to create a range of tests.\nThese range from single, real-time tests to complex, molecular tests\nperformed on Nanogen’s microarray systems.\nAs a pioneer of nanotechnology and miniaturized biotechnology, Nanogen\nexpects its broad intellectual property portfolio will have diverse\napplications and licensing opportunities in the future for medical diagnostics\nas well as other markets.\nThe Opportunity: Molecular Diagnostics\nNanogen’s broad suite of diagnostic products makes it possible for the\ncompany to take advantage of opportunities in the rapidly growing\nmolecular diagnostics industry. The molecular diagnostics market today is\nestimated to be approximately $1 billion and is expected to grow at a\nhealthy pace of 30 - 50 percent per year. This growth is fueled by a better\nunderstanding of the molecular basis of disease and the need for more\ngenetic tests to improve the prognosis and treatment of patients.\nBusiness Strategy\nNanogen’s strategy is to identify and\ncommercialize diagnostic tests that meet\nsignificant market needs. The company bolstered\nits capital structure and initiated a business\ndevelopment program to grow its revenue base.\nThe 2004 acquisition of SYNyX provided Nanogen\nwith a variety of point-of-care tests to\nimmediately add to its product portfolio. Later\nlast year, the merger with Epoch Biosciences\naugmented the product line with 25 complementary analyte specific\nreagents (ASRs) and other technologies for genetic analysis. These products\nfurther leverage Nanogen’s existing sales and marketing infrastructure.\nNanogen will continue to identify large volume as well as unique tests with\na focus on moving the diagnostic process and information closer to the point\nof physician and patient interaction. Nanogen will distribute its products\naround the world through licensing and distribution agreements as well as\ndirect sales efforts to continue to expand its business into new and growing\nmarkets in the U.S., Canada and abroad.\u003c\/div\u003e\u003cdiv\u003eProducts: Addressing Labs’ Needs\nMolecular Diagnostics \u0026amp; Genetic Testing\nAvailable in 2005, the NanoChip® 400 is Nanogen’s second generation\nadvanced molecular diagnostic testing and development platform for clinical\nresearch and clinical reference laboratories. The automated multi-purpose\nsystem facilitates detection of known genetic sequences using a 400-site\nNanoChip® Electronic Microarray. The NanoChip® 400 offers increased\nthroughput for running multiplex molecular assays on a smaller sized\ninstrument.\nNanogen’s suite of consumable products includes analyte specific reagents\n(ASRs) for laboratories to develop very simple tests for single mutations or\nmore complex tests for multiple genetic markers. The merger with Epoch\nBiosciences bolstered Nanogen’s line of ASRs by adding 25 complementary\nproducts, allowing Nanogen to offer a broader suite of solutions to its current\nand targeted customers. These MGB EclipseTM Detection Reagents are\ncompatible with many standard real-time PCR instruments for amplification\nand quantitation of samples. Nanogen’s internally developed ASRs utilize the\nNanoChip® microarray for more complex analysis of multiple markers. For\nexample, in 2005 the company will market a panel optimized for use with the\nNanoChip® 400 that detects the six most common respiratory viruses.\nThe first generation, open platform NanoChip® Molecular Biology\nWorkstation is a resource for researchers identifying the next set of\nmutations that could be useful as clinical assays. The system’s ability to test a\nuser defined set of mutations, called panels, on one chip makes it easier and\nmore cost-effective to use than research-grade thousand-gene chip arrays.\nNEXUSdx™ Point-of-Care Diagnostics\nNEXUSdx™ point-of-care diagnostic tests are marketed to healthcare\nprofessionals and research facilities in Europe and Canada by Nanogen’s\nsubsidiary, SYNyX. The highly specialized products diagnose disease at the\ninitial stages to allow for earlier treatment as well as to monitor treatment\neffectiveness and disease progression. Building expertise in cardiac related\nhealth conditions, SYNyX plans to offer an NT-proBNP diagnostic test for\ncongestive heart failure in 2005. Analysts predict the BNP market will have\nabove-average growth and will reach approximately $300 million by 2005 as\nuse increases internationally.\nUsing its Proteomics Discovery Platform™, SYNyX scientists have identified\nbiomarkers in stroke, insulin resistance, type II diabetes, congestive heart\nfailure, Alzheimer's disease and traumatic brain injury. These discovery\nefforts provide a deep pipeline of potential new and important products for\nthe point-of-care market.\nElectricity is what makes the NanoChip®\ndifferent and is a key technological\nadvantage. At the heart of Nanogen's\ntechnology is a tiny silicon chip called the\nNanoChip® Electronic Microarray. The\nNanoChip® 400 has 400 test sites upon which\ngenetic tests can be conducted. DNA and RNA\nare moved and concentrated by controlling\nthe current at each test site, improving\naccuracy, speed and flexibility. \u003c\/div\u003e\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003eComes as you see. Condition is uséd and shows minimal signs of use in a working environment. Removed from service in working condition. Does not come with any cables or software other than power cable.\u003cdiv\u003eIn effort to ship item with minimal chance of damage, we will be shipping via freight. Item will be palletized. When purchasing, please provide business name and shipping address that either has a loading dock or forklift so we can keep shipping costs down for you\u003c\/div\u003e\u003cdiv style=\"text-align:center; background:#fff; padding:5px 0px 5px 0px; clear:both; width:100%;\"\u003e\n\u003cdiv style=\"padding-bottom:5px;\"\u003e\n\u003cspan\u003eeBay integration\u003c\/span\u003e by \u003c\/div\u003e\n\u003cimg width=\"120\" src=\"https:\/\/d31wxntiwn0x96.cloudfront.net\/emgrhw\/\/images\/codisto-connect.png?width=200\u0026amp;nostretch\u0026amp;v=1\"\u003e\n\u003c\/div\u003e","brand":"Vast Trades","offers":[{"title":"Default Title","offer_id":49152257130723,"sku":null,"price":800.0,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0711\/7206\/3459\/files\/s-l1600_7d7a1946-9033-4e2c-abea-db3279358194.webp?v=1780596752","url":"https:\/\/vasttradesstore.com\/products\/nanogen-nanochip-400-178184775983","provider":"Vast Trades","version":"1.0","type":"link"}